Pharmaceuticals, Biotechnology and Life Sciences
Denali Therapeutics and Sanofi in partnership have started dosing patients in a clinical Phase 1b study of DNL747 in patients with ALS.
Swiss-based global biopharmaceutical company Debiopharm Group will break up partnership with Allergan, and will transfer commercialisation licence for Trelstar in the US and Canada.
OncoSec Medical Incorporated and GOG Foundation will jointly work to conduct a registration-enabled study of Tavo (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150), it was announced on Monday.
Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Stemedica Cell Technologies today announced positive results from its Phase I/IIa clinical study for the treatment of ischemic stroke.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, while the global pharmaceutical leader noted the positive results from the first Phase 3 trial were reported in June 2018.
A Dutch maker of of transformative RNA medicines for the treatment of severe genetic rare diseases, ProQR Therapeutics, has got the U.S. Food and Drug Administration (FDA) tips for a Phase 2/3 pivotal trial Illuminate for sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene, the leading genetic cause of childhood blindness.
Galapagos has discovered GLPG3312, a first generation compound against a novel and undisclosed inflammation target class, and it started Phase 1 trial.
Basilea Pharmaceutica posted preliminary revenue for the financial year 2018, which is expected to increase by 31% over 2017 to about CHF133 million (€118.37M), from the last year’s CHF101.5 million (€90.3M).
Axsome Therapeutics’ AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD), the company said Monday.